Home
CiplaMed
a valuable online resource for your practice
register login
Welcome to
  • Create new account
  • Request new password

Or log in with...

Join CiplaMed to:
  • Listen to masters of medicine
  • Stay updated through clinical news etc
  • Access presentations on diseases and products
  • Find information on Cipla products
More Sign up

Login With:

  • SPECIALITY
    • General Medicine
    • Cardiology
    • Critical Care Medicine
    • Dermatology
    • Diabetology
    • ENT
    • Gastroenterology & Hepatology
    • HIV / AIDS
    • Infectious Diseases
    • Musculoskeletal Diseases
    • Neuropsychiatry
    • Obstetrics & Gynecology
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Respiratory Medicine
    • Surgery
    • Urology
  • TOPICS
    • Allied Interventions in HIV/AIDS
    • Antiretroviral Management in Adults and Adolescents
    • Antiretroviral Management in Pediatrics
    • Epidemiology
    • HIV and Aging
    • HIV Resistance
    • HIV Testing
    • Management of Drug – Drug Interactions in HIV
    • Management of HIV in Key Populations
    • Management of Non-infectious Comorbidities in HIV
    • Opportunistic Infections and Coinfections
    • Post-exposure prophylaxis (PEP)
    • Pre-exposure Prophylaxis (PrEP)
    • Preventing Mother to Child Transmission
    • Primary Care in HIV
    • Treatment as Prevention (TasP)
  • SCIENTIFIC RESOURCES
    • Our Publications
    • Slide Library
    • Guidelines
    • Key Trials
    • Conference Proceedings
    • Patient Education
    • Clinical Tools
    • Journals
    • Useful Links
    • Our Publications
    • Slide Library
    • Guidelines
    • Our Research
    • Key Trials
    • Conference Proceedings
    • Patient Education
    • Clinical Tools
    • Device Demos
    • Journals
    • Useful Links
    • Expert's Viewpoint
  • Product Index
  • INTERACT
    • Blogs
    • Discussion Forum

Search form

You are here

Home»HIV / AIDS

Webcasts

Explore >>

Success After Failure: Moving beyond First-line Therapy

Medical News

Explore >>

Switch from Branded to Generic ARVs in Virologically Suppressed HIV Patients:...
17 Aug, 2017
Initiation of Efavirenz-based First-line ART and Risk of Suicidal Thoughts: Is...
14 Aug, 2017
Efficacy and Safety of RPV/FTC/TDF Based Single-tablet Regimen in HIV-1 Patients
11 Aug, 2017

New Content

Explore>>
  • Pre-exposure Chemoprophylaxis with Oral FTC–TDF Prevents HIV Acquisition in Men Who...
  • Highlights of the International Congress of Drug Therapy in HIV Infection - 2016...
  • Highlights of the 21st International AIDS Conference (AIDS 2016)

Our Publications

Explore>>
Antiretroviral Therapy – Current Recommendations
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets

Slide Library

Explore >>

HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
HIV- Post-exposure Prophylaxis (PEP)
Isoniazid Preventive Therapy in HIV Infection

Patient Education

Explore >>

Live Healthier, Live Longer
Living with Hope

Conference Proceedings

Explore >>

Highlights of the International Congress of Drug Therapy in HIV Infection - 2016
Highlights of the 21st International AIDS Conference (AIDS 2016)
Highlights of the 23rd Conference on Retroviruses and Opportunistic Infections...

Poll

The results of the START study document benefits of initiating ART early (CD4 > 500) in naïve patients. What would you recommend to your patients:
Initiate ART irrespective of CD4 counts
62% (8 votes)
Defer ART till CD4 counts drops to < 500 cells/mm3
23% (3 votes)
Defer ART till CD4 counts drops to < 350 cells/mm3
8% (1 vote)
None of the above
8% (1 vote)
Total votes: 13
CSV

Other Links

  • Guidelines
  • Clinical Tools
  • Journals
  • Useful Links
  • New Content
  • PG Quiz
  • Most Popular
  • Calendar
  • Product Index
  • NEW CONTENT
  • |
  • CONTACT US
  • |
  • ABOUT US
  • |
  • SITEMAP
  • |
  • PRIVACY POLICY
  • |
  • DISCLAIMER
  • |
  • WWW.CIPLA.COM
  • |
  • WWW.BREATHEFREE.COM
© Copyright 2017 -- All rights reserved  
Digital Partner : Indus Net Technologies